Charles Schwab Investment Management Inc. Sells 90,614 Shares of Organogenesis $ORGO

Key Points

• Charles Schwab Investment Management Inc. has decreased its stake in Organogenesis by 9.8%, holding approximately 0.66% of the company’s stock after selling 90,614 shares in the first quarter.
• Institutional investors have varied positions in Organogenesis, with Wealth Enhancement Advisory Services LLC growing its stake by 10.8% and other firms like Wells Fargo increasing theirs by 29.6%.
• Organogenesis reported a quarterly loss of ($0.09) EPS, missing estimates, and has set a fiscal year 2025 guidance with an average forecast of ($0.07) EPS.

Charles Schwab Investment Management Inc. cut its position in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 9.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 835,046 shares of the company's stock after selling 90,614 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.66% of Organogenesis worth $3,607,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Merit Financial Group LLC bought a new position in Organogenesis during the first quarter valued at approximately $45,000. ProShare Advisors LLC raised its stake in Organogenesis by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after purchasing an additional 6,689 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Organogenesis during the first quarter valued at $67,000. Algert Global LLC purchased a new stake in Organogenesis during the fourth quarter valued at $69,000. Finally, PDT Partners LLC purchased a new stake in Organogenesis during the fourth quarter valued at $110,000. 49.57% of the stock is owned by institutional investors.

Organogenesis Trading Up 1.4%

Shares of NASDAQ:ORGO traded up $0.07 during trading on Thursday, reaching $5.03. The company's stock had a trading volume of 1,266,777 shares, compared to its average volume of 701,069. Organogenesis has a 12 month low of $2.45 and a 12 month high of $6.71. The firm's 50 day simple moving average is $4.59 and its two-hundred day simple moving average is $4.21. The stock has a market capitalization of $638.11 million, a PE ratio of -35.93 and a beta of 1.75.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The firm had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%. Organogenesis has set its FY 2025 guidance at EPS. Research analysts anticipate that Organogenesis will post -0.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ORGO shares. Cantor Fitzgerald increased their price target on shares of Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a report on Friday, August 8th. BTIG Research reaffirmed a "buy" rating on shares of Organogenesis in a report on Tuesday, July 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $7.50.

Insider Transactions at Organogenesis

In other news, insider Lori Freedman acquired 9,022 shares of the firm's stock in a transaction on Friday, June 6th. The stock was acquired at an average price of $2.99 per share, with a total value of $26,975.78. Following the completion of the purchase, the insider directly owned 846,459 shares in the company, valued at approximately $2,530,912.41. This trade represents a 1.08% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 33.00% of the stock is currently owned by insiders.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.